Clinical trial
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of…
NCT00039910 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00039910 |
|---|---|
| Title | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia |
| Official title | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia |
| Intervention type | Drug |
| Interventions | (PN-152, 243)/ PN-196, 444 |
| Enrollment | 240 |
| Start date | Jul 1, 2000 |
| Completion | Mar 1, 2003 |
| First posted | Jun 17, 2002 |
| Last update posted | May 4, 2007 |
| Countries | Australia, France, Greece, Hong Kong, Poland, Russia, Singapore, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: